These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16887118)

  • 21. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice.
    Tong XK; Nicolakakis N; Fernandes P; Ongali B; Brouillette J; Quirion R; Hamel E
    Neurobiol Dis; 2009 Sep; 35(3):406-14. PubMed ID: 19524673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy.
    Breyhan H; Wirths O; Duan K; Marcello A; Rettig J; Bayer TA
    Acta Neuropathol; 2009 Jun; 117(6):677-85. PubMed ID: 19387667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis.
    Marcello E; Epis R; Di Luca M
    Eur J Pharmacol; 2008 May; 585(1):109-18. PubMed ID: 18377893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
    Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
    Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excitatory synaptic transmission is depressed in cultured hippocampal neurons of APP/PS1 mice.
    Priller C; Mitteregger G; Paluch S; Vassallo N; Staufenbiel M; Kretzschmar HA; Jucker M; Herms J
    Neurobiol Aging; 2009 Aug; 30(8):1227-37. PubMed ID: 18077058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plaques, tangles, and memory loss in mouse models of neurodegeneration.
    Eriksen JL; Janus CG
    Behav Genet; 2007 Jan; 37(1):79-100. PubMed ID: 17072762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
    He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
    Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged stress will induce Alzheimer's disease in elderly people by increased release of homocysteic acid.
    Hasegawa T
    Med Hypotheses; 2007; 69(5):1135-9. PubMed ID: 17499446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression?
    Small DH
    Trends Mol Med; 2008 Mar; 14(3):103-8. PubMed ID: 18262842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model.
    Kurinami H; Sato N; Shinohara M; Takeuchi D; Takeda S; Shimamura M; Ogihara T; Morishita R
    Int J Mol Med; 2008 May; 21(5):531-7. PubMed ID: 18425343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease.
    Onozuka H; Nakajima A; Matsuzaki K; Shin RW; Ogino K; Saigusa D; Tetsu N; Yokosuka A; Sashida Y; Mimaki Y; Yamakuni T; Ohizumi Y
    J Pharmacol Exp Ther; 2008 Sep; 326(3):739-44. PubMed ID: 18544674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hippocampal synaptic activity, pattern separation and episodic-like memory: implications for mouse models of Alzheimer's disease pathology.
    Palmer A; Good M
    Biochem Soc Trans; 2011 Aug; 39(4):902-9. PubMed ID: 21787321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and future therapy in Alzheimer's disease.
    van Marum RJ
    Fundam Clin Pharmacol; 2008 Jun; 22(3):265-74. PubMed ID: 18485144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse.
    Chen Q; Nakajima A; Choi SH; Xiong X; Tang YP
    J Neurosci Res; 2008 May; 86(7):1615-25. PubMed ID: 18189321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic analysis of response to traumatic brain injury in a mouse model of Alzheimer's disease (APPsw).
    Crawford FC; Wood M; Ferguson S; Mathura VS; Faza B; Wilson S; Fan T; O'Steen B; Ait-Ghezala G; Hayes R; Mullan MJ
    Brain Res; 2007 Dec; 1185():45-58. PubMed ID: 17961517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes.
    Pugliese M; Gangitano C; Ceccariglia S; Carrasco JL; Del Fà A; Rodríguez MJ; Michetti F; Mascort J; Mahy N
    Brain Res; 2007 Mar; 1139():85-94. PubMed ID: 17292335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.